Two tests and one reference [General Sta­tis­tics]

posted by Brus – Spain, 2020-08-31 11:58 (2102 d 22:14 ago) – Posting: # 21895
Views: 13,977

Dear Helmut and all,

If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?

In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).

If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?

Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?

Best regards,

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
299 visitors (0 registered, 299 guests [including 32 identified bots]).
Forum time: 10:12 CEST (Europe/Vienna)

I’m all in favor of the democratic principle
that one idiot is as good as one genius, but I draw the line
when someone takes the next step and concludes
that two idiots are better than one genius.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5